Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease
Nephrology Dialysis Transplantation · 29.08.2025 · 40 (9) · 1746-1755
DOI: 10.1093/ndt/gfaf046 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 07.03.2025. Verfasst von Wisanne M Bakker und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Renal Insufficiency, Chronic, Sodium-Glucose Transporter 2 Inhibitors. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dutch Kidney Foundation, National Health and Medical Research Council of Australia, National Medical Research Council (NMRC) Singapore.
Abstract (Originalsprache)
Background
Several clinical trials have shown beneficial effects of sodium–glucose co-transporter 2 (SGLT2) inhibitors on kidney disease progression and cardiovascular morbidity and mortality in patients with chronic kidney disease (CKD) with and without type 2 diabetes mellitus. However, some subgroups of patients with CKD have been excluded from participation in these trials, such as patients with severely impaired kidney function, patients on dialysis and kidney transplant recipients.
Methods
The Renal Lifecycle trial (NCT05374291) is a pragmatic, international, multicentre, investigator-initiated, randomized, placebo-controlled clinical trial planned to enrol ≈1500 patients with an estimated glomerular filtration rate (eGFR) ≤25 ml/min/1.73 m2, on haemodialysis or peritoneal dialysis or after a kidney transplant and an eGFR ≤45 ml/min/1.73 m2, who will be randomized 1:1 to receive either dapagliflozin 10 mg once daily or matching placebo.
Results
The primary endpoint is a composite of heart failure hospitalization, all-cause mortality or, for those not on dialysis, kidney failure (start of dialysis >1 month, receiving a kidney transplant or death due to kidney failure). The trial is event driven, indicating that it will end after 468 first primary endpoint events have occurred, with a power of 80% and an α of 0.05 to detect a 25% relative risk reduction assuming an annual 12.5% incidence of the primary outcome. The secondary endpoints include a separate analysis of the incidence of each component of the primary endpoint in the overall trial population as well as the incidence of the combined primary endpoint in each of the three subgroups of patients. Other (exploratory) endpoints are efficacy, safety, tolerability, health-related quality of life and cognition.
Conclusion
The Renal Lifecycle trial aims to investigate the effects of the SGLT2 inhibitor dapagliflozin compared with placebo on the incidence of kidney failure, heart failure, mortality and safety in three subgroups of patients with advanced CKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
- Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
- George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia.
- Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
- Department of Nephrology, University Hospital Wurzburg, Wurzburg, Germany.
- Department of Nephrology and Hypertension, University Medical Center Utrecht, Utrecht, The Netherlands.
ORCID-Profile: Wisanne M Bakker, Hiddo J L Heerspink, Stefan P Berger, Christoph Wanner, Clare Arnott, Jose L Górris, Marc G Vervloet, Aiko P J de Vries
Förderung
- Dutch Kidney Foundation
- National Health and Medical Research Council of Australia
- National Medical Research Council (NMRC) Singapore
- AstraZeneca
Zitieren
APA
Bakker, W. M., Heerspink, H. J. L., Berger, S. P., Wanner, C., Badve, S. V., Arnott, C., Abrahams, A. C., van den Born, J. C., van Faassen, T. C., Gaillard, C. A. J. M., Gelens, M. A. C. J., Górris, J. L., Hemmelder, M. H., Jakulj, L., van Kruijsdijk, R. C. M., Kuypers, D. R. J., van der Meer, P., van der Net, J. B., Nijmeijer, H. H., …, & Renal Lifecycle Trial Investigators (2025). Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease. Nephrology Dialysis Transplantation, 40(9), 1746-1755. https://doi.org/10.1093/ndt/gfaf046
Vancouver
Bakker WM, Heerspink HJL, Berger SP, Wanner C, Badve SV, Arnott C, et al. Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease. Nephrology Dialysis Transplantation. 2025;40(9):1746-1755. doi:10.1093/ndt/gfaf046
BibTeX
@article{Bakker2025,
author = {Bakker, Wisanne M and Heerspink, Hiddo J L and Berger, Stefan P and Wanner, Christoph and Badve, Sunil V and Arnott, Clare and Abrahams, Alferso C and van den Born, Joost C and van Faassen, Tim C and Gaillard, Carlo A J M and Gelens, Mariëlle A C J and Górris, Jose L and Hemmelder, Marc H and Jakulj, Lily and van Kruijsdijk, Rob C M and Kuypers, Dirk R J and van der Meer, Peter and van der Net, Jeroen B and Nijmeijer, Heleen H and Vervloet, Marc G and de Vries, Aiko P J and Walsh, Michael and Wang, Angela Y and Gansevoort, Ron T and Renal Lifecycle Trial Investigators, Renal Lifecycle Trial Investigators},
title = {Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease},
journal = {Nephrology Dialysis Transplantation},
year = {2025},
volume = {40},
number = {9},
pages = {1746--1755},
doi = {10.1093/ndt/gfaf046}
}
EUVIMED